Weekly MI Briefing — Keytruda

Week ending 19 Aug 2026 | Baseline week

1. This week’s recurring question themes

• Brand, substitution, and comparative questions — 5 questions / 30 responses:
  People asked whether Keytruda can be substituted at the pharmacy; whether it has a generic or biosimilar; how it compares with Opdivo and Tecentriq; how oncologists choose between PD-1/PD-L1 agents; and whether claims that Keytruda is “more effective” than Opdivo are supported by head-to-head trials. Biosimilar/generic language appeared 13 times and hedging appeared frequently.
• Labeled dosing and administration — 2 questions / 12 responses:
  Questions covered the adjuvant regimen for resected melanoma (“how often and the duration”) and administration details, including infusion time, dilution/rate, premedication, and flushing.
• Immune-mediated laboratory management — 1 question / 6 responses:
  “Hold dose vs permanently discontinue” for elevated AST/ALT and the applicable thresholds.
• Interactions — 1 question / 6 responses:
  Warfarin and CYP/P-gp interaction concerns.
• Eligibility and special populations — 1 question / 6 responses:
  Contraindications or avoidance in patients with prior organ transplant or active autoimmune disease. Pregnancy/lactation, inflammatory bowel disease, and hypersensitivity terms were prominent.

2. Where no consistent answer currently exists

The clearest MI-relevant inconsistency concerns:

• Administration instructions: Asked as a detailed practical question about infusion time, dilution, infusion rate, premedication, and flushing. Only 2 of 6 answer variants included the flagged contraindication-related content; 4 omitted it. This means a person asking how Keytruda is administered may receive materially different levels of completeness depending on the assistant.
• Warfarin/CYP/P-gp interactions: 1 of 6 variants included the flagged contraindication-related category and 5 omitted it. Although responses generally stated that a classic CYP/P-gp interaction is not expected, the surrounding labeled interaction/monitoring explanation was not consistently surfaced.
• Eligibility/special populations: Infection-risk content appeared in 4 of 6 variants and was omitted in 2. Responses varied in how they separated a formal contraindication from situations requiring caution, including transplant and autoimmune disease.

These are real questions being asked now; the answer a person receives today depends on which AI assistant or answer variant they use. This is exactly the gap an MI-approved SRD can close.

3. Off-label and substitution questions

No off-label or compounded-substitution questions were tagged this week. Therefore, there is no evidence of current AI demand for those topics in this sample, and no basis to create an off-label or compounding SRD solely from this week.

Substitution/biosimilar demand is clear: two recurring brand questions, representing 12 responses, asked whether Keytruda has an equivalent generic/biosimilar and whether substitution occurs at the pharmacy. Answers were consistently hedged around country, coverage, prescribing rules, and availability, but several excerpts broadly asserted that pembrolizumab biosimilars exist or may be available. This suggests existing SRD content is not being surfaced as a clear, jurisdiction-specific answer. Review current substitution/biosimilar content for currency and precise terminology.

4. Trend across weeks

This is a baseline week: previous_week_available is false and the trend history contains only 19 Aug. No recurring or growing pattern across weeks can yet be established. The three inconsistency flags should be treated as initial prioritization signals, not trends.

5. Recommended actions

1. Update/review the Keytruda administration SRD for currency — include labeled infusion duration, preparation/dilution, rate, line flushing, and premedication instructions in one complete answer. Trigger: detailed administration question plus inconsistency across 4/6 variants.
2. Create or update an interaction SRD for warfarin and CYP/P-gp substrates — clearly distinguish absence of a classic labeled interaction from practical monitoring considerations. Trigger: 6 responses, with content inconsistency in 5/6.
3. Create/update an eligibility and special-populations SRD — separate formal contraindications from cautionary situations involving transplant, autoimmune disease, infection, pregnancy/lactation, and hypersensitivity. Trigger: 6 responses and inconsistent infection-risk coverage.
4. Review the biosimilar/generic and substitution SRD/FAQ — specify that availability and interchangeability are jurisdiction-dependent and distinguish biosimilar substitution from therapeutic alternatives. Trigger: 12 responses and 13 biosimilar/generic tags.
5. Monitor comparative-effectiveness questions; no new SRD yet — five brand questions show demand for Opdivo/Tecentriq comparisons, but this week’s data primarily reflects comparative framing rather than a defined MI content gap.